Get started
Work

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Year: 2021
Type: article
DOI: 10.1016/j.annonc.2021.02.011
Authors: L. Du, C. Yau, L. Brown-Swigart, R. Gould, G. Krings, G.L. Hirst, I. Bedrosian, R.M. Layman, J.M. Carter, M. Klein, S. Venters, S. Shad, M. van der Noordaa, A.J. Chien, T. Haddad, C. Isaacs, L. Pusztai, K. Albain, R. Nanda, D. Tripathy, M.C. Liu, J. Boughey, R. Schwab, N. Hylton, A. DeMichele, J. Perlmutter, D. Yee, D. Berry, L. van't Veer, V. Valero, L.J. Esserman, W.F. Symmans
Institutions: The University of Texas MD Anderson Cancer Center, University of California, San Francisco, Mayo Clinic, University of Minnesota, Georgetown University, Yale University, Loyola University Chicago, University of Chicago, University of California San Diego, University of Pennsylvania
Language: English
Subfield: Cancer Research
Open Access status: bronze
Funders: Foundation for the National Institutes of Health, Breast Cancer Research Foundation, Cancer Prevention and Research Institute of Texas, National Institutes of Health, National Cancer Institute, Center for Biomedical Informatics and Information Technology, National Cancer Institute
OpenAlex ID: W3131379307
FWCI: 2.717
Cites: 33
Cited by: 46
Related to: 10